Over the past six months, BioNTech's stock (BNTX) experienced fluctuations influenced by several key events: In August 2026, BioNTech reported sharply lower Q2 2026 COVID-19 revenues and wider losses, leading to a cut in full-year guidance, though it highlighted substantial cash reserves and 14 pivotal oncology trials as future growth drivers. New EU authorization for a 2026-2027 XFG-adapted COVID-19 vaccine with Pfizer in August 2026 helped maintain a seasonal revenue stream. A leadership transition was announced in August 2026, with Guido Oelkers set to replace founder-CEO Ugur Sahin by 2027, signaling a strategic shift towards a diversified oncology and biopharma platform. In November 2026, BioNTech reported Q3 2026 results that surpassed analyst expectations for both earnings and revenue, despite a 15% year-over-year decline in revenue due to lower COVID-19 vaccine demand, leading to a raised full-year 2026 revenue guidance midpoint to €1.7-1.9 billion. Oncology pipeline advancements were highlighted in October-November 2026, including encouraging global Phase 2 data for pumitamig in advanced NSCLC, the advancement of a global Phase 3 clinical trial for pumitamig in combination with sacituzumab govitecan in triple-negative breast cancer, and data showing gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer. However, a Phase II trial of autogene cevumeran for colorectal cancer was discontinued in November 2026 due to a numerical imbalance in overall survival. Additionally, the Phase III trial of trastuzumab pamirtecan in hormone receptor-positive, HER2-low metastatic breast cancer met its primary endpoint with a statistically significant but modest improvement in progression-free survival, though a higher rate of interstitial lung disease was reported in November 2026. As of November 2, 2026, the share price was $87.48, representing a decline of 16.55% from November 4, 2025, and an 18.30% change over the past year, with a 52-week range between $79.52 and $124.00.